- About About
Medical Patient Resources Become a Legal Medical Marijuana Patient Talking to your doctor Medical Marijuana Conditions in Your Area The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- News News
- Join Join
Mississippi Medical Marijuana Laws and Regulations
In 2014, Mississippi passed HB 1231, which included a section known as “Harper Grace’s Law” which creates an affirmative defense for the possession and use of cannabis oil containing high concentrations of CBD (one of the compounds founds in cannabis) in very limited circumstances. Legal protection is only available to patients (and their parent, guardian or custodian) diagnosed with a debilitating epileptic condition or related illness, and only if the CBD oil was either obtained from or tested by the National Center for Natural Products Research at the University of Mississippi and dispensed by the Department of Pharmacy Services at the University of Mississippi Medical Center.
In 2017, the legislature passed SB 2610, to clarify the use of cannabidiol in research for the treatment of seizures and other medical conditions.
HB 1231 (2014) - creates an affirmative defense for the possession and use of cannabis oil containing high concentrations of CBD
SB 2610 (2017) - clarifies the use of cannabidiol in research for the treatment of seizures and other medical conditions.